A report released by the World Health Organization in 2017 mentioned that about 322 million people suffer from depression worldwide; according to the "2022 National Depression Blue Book", the number of people suffering from depression in my country is as high as 95 million, but the treatment rate is only 9.5%. As social pressure increases, more and more people have mental health problems, the number of patients with depression continues to increase, and the demand for antidepressants continues to increase. According to Grand View Research, the global antidepressant market size will reach US$60 billion in 2028.

At present, although there are many antidepressants available clinically, most drugs still have defects such as slow onset, low efficiency, and even sexual dysfunction and cognitive impairment. Therefore, patients still need more new and effective antidepressants.

LPM682000012 is a Class 1 new drug declared by Luye Pharmaceuticals. The indication for clinical trials approved this time is depression. In addition, Luye Pharma has another Class 1 innovative drug, "Torudivenlafaxine Hydrochloride" (LY03005), which has been approved in China for the treatment of depression. The drug is also being developed for the treatment of generalized anxiety disorder.

LPM682000012 is another innovative drug that Luye Pharma has deployed in the field of antidepressants, and is expected to bring new ways to treat depression.

https://news.yaozh.com/